share_log

Neumora Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ARCH Venture Fund VII, L.P.(20.9%),ARCH Venture Fund VIII Overage, L.P.(20.9%), etc.

Neumora Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-ARCH Venture Fund VII, L.P.(20.9%),ARCH Venture Fund VIII Overage, L.P.(20.9%)等

美股SEC公告 ·  2023/12/15 17:06
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息